Compare Citius Pharmaceuticals Inc (CTXR) vs SK Telecom Co. Ltd. Common Stock (SKM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SK Telecom Co. Ltd. Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while SK Telecom Co. Ltd. Common Stock trades at $34.56 (market cap $13.36B). The key difference: SK Telecom Co. Ltd. Common Stock is far larger — about 980.9× Citius Pharmaceuticals Inc's market cap, and SK Telecom Co. Ltd. Common Stock pays a 2.85% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and SK Telecom Co. Ltd. Common Stock for 1 Days on average.
| CTXR | SKM | |
|---|---|---|
Market Cap | $13.62M | $13.36B |
Volume | 132,438 | 1,302,042 |
Sector | Health | Media |
52-Week High | $1.82 | $46.00 |
52-Week Low | $0.48 | $19.68 |
Typical Hold Time | 17 Days | 1 Days |
Enterprise Value | $3.79M | $19.41B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SK Telecom Co. Ltd. Common Stock
SK Telecom is a South Korean telecommunications company providing mobile, broadband, and digital services. It also develops services in areas such as AI, cloud, and data centers.
Read more on SKM →
